Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab vs 19 not. Betw group outcomes same: PFTs, O2 use, Infx, Resp admissions, mortality. RTX group recv more immunosuppressives. https://t.co/sle4a0JOFL https://t.co/SyhK12KhHY

Rheumatoid Arthritis Faculty Panel Q&A This expert panel from https://t.co/4UQlqwujiR 2026 brings together leading faculty to address real-world challenges in RA care, offering practical insights you can apply immediately in practice. 🎧 Listen here: https://t.co/DfGDbKUGoD https://t.co/TpCAIUyGF2

A LESSON FOR GC OVERUSE: Inappropriate PPI use was Twice as successful w/ reduced w/ GP & Pt-facing intervention (15 vs 7%) vs usual care or GP-only intervention. Study of 1498 GPs, 34K pts https://t.co/4cxoeanAK8 https://t.co/FdfUdST40o

Opioids Down, Gabapentins Up The number of U.S. patients prescribed long-term opioid therapy declined from 2015 to 2023, but co-prescribing of opioids with gabapentinoids increased, prescription data showed. https://t.co/iXEUfR18Is https://t.co/6DCUvGAW6N

Top Four and More (4.10.2026) Dr. Jack Cush reviews the news and journal reports from RheumNow this week - including his top four favorite subjects. https://t.co/TUPky5m1Mo https://t.co/QRgh9SqcOF

NHIS 10yr survey of 195,600 Americans shows Chronic pain assoc w/ double rates of smoking & vaping. Smoking decr over time, but always higher in chronic pain pts (17.7% 2014, 13.1% in 2023) than w/o pain (12.5% 2014, 7.5% 2023). E-cigs incr over time, more w/ chronic pain https://t.co/iW7IDwHyJa

Potential new mechanism of MTX Effx - MTX polyglutamates accumulates in monocytes by D5, modulates transcriptional signature “non-classical monocyte”-assoc genes by Wk4, & predicts MTX responses https://t.co/g14GONKgvq https://t.co/oyoua9xAN4

Malignancies Not Increased with Biologic Therapies The risk of malignancy in RA patients receiving biologic agents was evaluated by metanalysis of RCTs and found no significant increased risk of malignancy compared with other DMARDs or with placebo. https://t.co/LM87wLjNoM https://t.co/KPGCcD7Q39

JAMA Guideline on the Management of Crohn Disease https://t.co/GV0lICS8Sn https://t.co/aFWH5Tl4Jv

OL phase 2 study 50 active systemic JIA pts Randomized to IL-1 inhibitor, firsekibart or TCZ q2wk x 24 wks. At day 28, modified ACR Pedi 30response (no fever) favored FIRS 3mg dose (94% vs 75% vs 82%). Also higher ACR Pedi 70/90 responses & steriod tapers. https://t.co/8bdCLUFFLT https://t.co/ddQe7k25UE

Global Study of #gout - incidence increased by 158% (from 1990 to 2023), during which mean onset agerose from 58 to 62 years; but % young-onset gout dropped 15.8% to 9.8%. #s due to aging, not younger onset. https://t.co/5pqMwPEnuj https://t.co/414vJHnBYi

2023 FDA’s removal of REMS in-person Rx requirement for mifepristone was assoc w/ large increase in mifepristone Rx at pharmacies (most thru mail order where abortion is legal and telehealth Rxing is permitted https://t.co/9NHMmxUpLl https://t.co/jkV5DmIaJt